【Animal modeling】-Exploration of the protective effect of bifidobacteria on liver function in rats with chronic alcoholic liver injury

  Objective: To investigate the protective or influence of bifidobacteria on liver function in rats with chronic alcoholic liver injury, and to explore its mechanism preliminarily.

  METHODS: SD rats were randomly divided into CALI group, metadoxine (90 mg/kg) group, BIFI low (500 mg/kg), medium (1000 mg/kg) and high (2000 mg/kg) dose groups, The silent information regulatory protein 1 (SIRT1) inhibitor Tenovin-6 (25mg/kg) group. The CALI group and the blank control group were given an equal volume of normal saline by gavage. After 8 weeks, the liver function of the rats in each group was analyzed; The levels of TG and TC in liver tissue and serum were detected; hematoxylin-eosin (HE) staining was used to observe the pathological changes of liver tissue; Western blotting (WB) method was used to analyze the expression of SIRT1 and chREBP in liver tissue.

  Results: Compared with the control group, the liver function of the CALI group was significantly decreased, the levels of ALT and AST in the blood were significantly increased (P<0.05), the liver tissue showed fatty pathological damage, and the levels of TG and TC in the liver tissue and serum were significantly increased. High (P<0.05), SIRT1 protein expression was significantly decreased (P<0.05), chREBP protein expression was significantly increased (P<0.05); significantly enhanced, the levels of ALT and AST in blood were significantly decreased (P<0.05), the pathological damage of liver tissue was significantly alleviated, the levels of TG and TC in liver tissue and serum were significantly decreased (P<0.05), and the expression of SIRT1 protein was significantly increased (P<0.05). 0.05), the expression of chREBP protein was significantly decreased (P<0.05). The above effects could be reversed by the SIRT1-specific inhibitor Tenovin-6.

  Conclusion: BIFI may inhibit lipid accumulation by regulating the expression of SIRT1/ChREBP, and achieve protection against chronic alcoholic liver injury in rats.